TTrialPathMatch Me to Trials
← Back to trials
RecruitingType2diabetesDiabetic Kidney Disease

NAD Augmentation in Diabetes Kidney Disease

Eligible age

30+ yrs

Accepts

All genders

Locations

1 state

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

A phase 2a trial randomized, double-blind, placebo-controlled, parallel group trial to determine whether NMN administration improves DKD, as indicated by a significantly greater reduction in UACR compared with placebo administration. Eligible participants will be randomized to receive either 1000 mg NMN or placebo twice daily.

Sponsor: Brigham and Women's Hospital

You may qualify if…

  • ✓ 1. A man or a postmenopausal woman (complete cessation of menses for one or more years and /or FSH \> 20 U/L), 30 years or older
  • ✓ 2. Has type 1 or type 2 diabetes mellitus, as indicated by any of the following:
  • ✓ 1. Self-report of type 1 or type 2 diabetes plus the use of a prescribed medication.
  • ✓ 2. ICD-10 code for type 1 or type 2 diabetes plus current use of a medication in the electronic medical record.
  • ✓ 3. HbA1c \>6.4%; or 2 fasting glucose \> 125 mg/dL
  • ✓ 3. Has an average of two or more morning UACR equal to or above 100mg/g creatinine each of which must be equal to or greater than 60 mg / g creatinine with at least one UACR value measured during the screening visit.
  • ✓ a. Recent UACR value in the medical record within the preceding 3 months prior to screening is acceptable.
  • ✓ 4. If type 2 diabetic and UACR is \> 300 mg/g creatinine, must be currently using an ACE inhibitor or an ARB or a SGLT2 inhibitor.

You may not qualify if…

  • ✕ 1. Fasting morning UACR \> 5,000 mg/ g creatinine
  • ✕ 2. Other laboratory abnormalities:
  • ✕ 1. Has AST or ALT \> 3 times the upper limit of normal
  • ✕ 2. eGFR \< 25 mL/ min / 1.73 m2
  • ✕ 3. Hematocrit \< 0.34 or \> 0.50 L/L
  • ✕ 3. A major adverse cardiovascular event in preceding 3 months
  • ✕ 4. Participation in an investigational trial to evaluate pharmaceuticals or biologics within the past 3 months or 5 half-lives, whichever is shorter
  • ✕ 5. Current alcohol or substance use disorder or dependence (DSM 5 criteria).

Where it's recruiting

Massachusetts

Boston

Source: ClinicalTrials.gov · NCT05759468 · last updated 2026-04-13

NAD Augmentation in Diabetes Kidney Disease · TrialPath